Oral Administration of the NMDA Receptor Antagonist S-Ketamine as Add-On Therapy of Depression: A Case Series
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We intended to assess safety, response to treatment and time to response of 1.25 mg/kg oral S-ketamine as add-on to standard antidepressants in four depressed patients. Two patients with melancholic depression responded early and stayed in remission, while two patients with distinct somatic symptoms, chronicity or atypical features did not respond. The limited number of patients does not allow conclusions about efficacy. Oral S-ketamine was well tolerated and could merit being studied in randomised controlled trials due to its higher practicability compared to (S-)ketamine infusion therapy. Clinical subtyping should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Onset of action of antidepressants: results of different analyses
Thompson, C. (2002) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.386 · Cited by 92
Cited by
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Side-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond
Krystal, J. H., Sanacora, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.026 · Cited by 406
R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357
The role of ketamine in treatment-resistant depression: A systematic review
Serafini, G., Howland, R., Rovedi, F., Girardi, P., & Amore, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140619204251 · Cited by 234
“[28] showed that a significant improvement was obtained with the use of ketamine in two patients whereas no significant side effects were reported.”
Serial infusions of low-dose ketamine for major depression
Rasmussen, K. G., Lineberry, T. W., Galardy, C. W., Kung, S., Lapid, M. I., Palmer, B. A., Ritter, M. J., Schak, K. M., Sola, C. L., Hanson, A. J., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113478283 · Cited by 217
“Some case report literature seems to support oral use of ketamine (Irwin and Iglewicz, 2010; Paslakis et al., 2010).”
BackgroundA REVIEW OF KETAMINE ABUSE AND DIVERSION: Review: Ketamine
Sassano-Higgins, S., Baron, D., Juarez, G., Esmaili, N., & Gold, M. (2016) · Depression and Anxiety · doi:10.1002/da.22536 · Cited by 204
Iadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201
Naughton, M., Clarke, G., O′Leary, O. F., Cryan, J. F., & Dinan, T. G. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.11.014 · Cited by 190
“A case series of 4 patients Paslakis et al., (2010) were administered oral S-ketamine at a dose of 1.25 mg/kg for 14 days alongside traditional antidepressants in an effort to shorten time to onset of action and in 2 of these patients there was a rapid and sustained improvement in mood within the fi…”
MethodInfluentialAlnefeesi, Y., Chen-Li, D., Krane, E., Jawad, M. Y., Rodrigues, N. B., Ceban, F., Di Vincenzo, J. D., Meshkat, S., Ho, R. C. M., Gill, H., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.04.037 · Cited by 186
Andrade, C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17f11738 · Cited by 178
Lee, E. E., Della Selva, M. P., Liu, A., & Himelhoch, S. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.01.003 · Cited by 124
“Logistically, given the chronic nature of depressive symptoms, an oral formulation would be preferable and has been shown to be an effective add-on to standard antidepressants in a few case studies [42].”
BackgroundOral ketamine for the treatment of pain and treatment-resistant depression
Schoevers, R. A., Chaves, T. V., Balukova, S. M., Rot, M. A. H., & Kortekaas, R. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.165498 · Cited by 81
Wang, J., Wang, Y., Xu, X., Peng, S., Xu, F., & Liu, P. (2020) · Medical Science Monitor · doi:10.12659/msm.922028 · Cited by 81
“25 mg/kg) improved 50% depression symptoms [24].”
Rapid-acting antidepressant strategies: mechanisms of action
Bunney, B. G., & Bunney, W. E. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000927 · Cited by 79
“Three case reports included the evaluation of the antidepressant effects of S-ketamine [ketamine is a racemic mixture of S- and R-enantiomers ; animal data suggest that S-ketamine is more potent and has less psychotomimetic sideeffects than R-ketamine (Hempelmann & Kuhn, 1997 ; Kohrs & Durieux, 1998 ; Raeder & Stenset…”
MethodInfluential
Metadata
- Authors
- Paslakis, G., Gilles, M., Meyer-Lindenberg, A., & Deuschle, M.
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 2009-12-11
- Volume
- 43
- Issue
- 01
- Pages
- 33-35
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W1986008985
- Cited by
- 66
- References
- 4
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.